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SEROTONIN 5-HT4 AGONIST ACTIVITY OF A SERIES OF 
MESO-AZANORADAMANTANE BENZAMIDES 
 
Daniel P. Becker,a* Roger Nosal,a Clara I. Villamil,a Gary Gullikson,b 
Chafiq Moummi,b Dai-Chang Yang,b and Daniel L. Flynn,a* 
 
Departments of Medicinal Chemistrya and Pharmacology,b 
Searle Research & Development, 4901 Searle Parkway, Skokie, IL 60077 
 
Abstract:  A series of meso-amino(methyl)azanoradamantane benzamides have been prepared and evaluated 
for 5-HT4 agonism activity in the rat tunica muscularis mucosae (TMM) assay.  Compound 8i is the most 
potent 5-HT4 agonist in the series, with an EC50 of 217 nM. 
 
 The serotonin 5-HT4 receptor has been identified in a variety of tissues and mediates an impressive 
array of functional responses.1  The 5-HT4 receptor was first described by Dumuis and Bockaert2 in mouse 
embryo colliculi neurons and by Craig and Clarke3  in guinea-pig ileum.  Furthermore, agonist activity at this 
receptor has been correlated with gastrointestinal prokinetic activity of prokinetic benzamides, including 
metoclopramide, zacopride, cisapride and renzapride.4  Novel and potent 5-HT4 agonists have potential in 
treating gastrointestinal motility disorders including reflux esophagitis, non-ulcer dyspepsia (NUD) and the 
irritable bowel syndrome (IBS).  Continuing efforts in this area have led to a number of potent agonists for the 
5-HT4 receptor.5 
 In earlier communications6 we disclosed a series of azaadamantane and azanoradamantane benzamides, 
including the potent 5-HT4 agonist/5-HT3 antagonist, SC-52491, which has an EC50 of 51 nM in the tunica 
muscularis mucosae assay and a Ki of 1.2 nM at the 5-HT3 receptor.  SC-52491 is also highly selective versus 
other monoamine receptors, with IC50s >10,000 nM for serotonin 5-HT1 and 5-HT2 receptors; dopamine D1 
and D2 receptors; alpha-1, alpha-2 and beta adrenergic receptors; as well as muscarinic and substance P 
receptors.  We previously described the synthesis of the anti-4(R)-amino derivative of azacycle I6a,7 for the 
preparation of SC-52491, which contains four contiguous asymmetric centers.  We subsequently focussed our 
attention on a series of azanoradamantanes as serotonergics in order to capitalize on their conformationally 
rigid structure to produce analogs with high potency and selectivity. We were specifically attracted to achiral 
substituted azanoradamantane scaffolds which exhibit a plane of symmetry.  Benzamides produced from these 
scaffolds would obviate the need for either asymmetric synthesis or resolution. 
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 The azanoradamantane skeleton possesses two nonequivalent bridgehead positions.  Incorporation of a 
nitrogen atom at either of these two bridgehead positions leads to two isomeric azanoradamantanes, I and II 
(Figure I).  Both I and II belong to the Cs symmetry group and as such are meso-structures.  This symmetry is 
retained if substitution is made at the 5-position on azanoradamantane I or at the 8-position of 
azanoradamantane II. 
 Compounds containing the meso-azanoradamantane skeleton of type I have not been reported in the 
literature.  Azanoradamantanes of type II had previously been synthesized by Speckamp,8 and this skeleton is 
present in natural products, including (+)-aristofruticosane.9 Herein we describe the 5-HT4 and 5-HT3 
properties of novel benzamide derivatives of amino(alkyl) derivatives of both isomeric meso-
azanoradamantanes I and II.  The requisite amino(alkyl)azanoradamantanes are shown in Figure II.   
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 The aminomethylazanoradamantane Ia was prepared as shown in Scheme I.  Reduction of 1,7 prepared 
by our tandem atom-transfer radical cyclization/ionic cyclization methodology, was reduced with lithium 
borohydride to give the diol 2.  Treatment with an excess of tosyl chloride gave the bis-tosylate which was 
deprotected with trifluoroacetic acid and cyclized with cesium chloride to give the azanoradamantane tosylate 3 
in excellent yield.  Displacement of the neopentyl tosylate with azide followed by reduction with lithium 
aluminum hydride gave aminomethyl azanoradamantane Ia. 
 The homologated derivative Ib was prepared via treatment of the azanoradamantane tosylate 3 with 
potassium cyanide followed by reduction with lithium aluminum hydride to give the aminoethyl 
azanoradamantane Ib (Scheme II). 
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 The isomeric endo- and exo-aminoazanoradamantanes of type II were prepared from 
azanoradamantanone 48 by reduction of the O-benzyloxime to give endo-10 and exo-IIa10 as a 1:1 mixture 
(Scheme III).  Alternatively, reductive homologation of azanoradamantone 4 with tosylmethyl isocyanide 
(TosMIC),11 as we had done previously on 1-azaadamantan-4-one,12 gave the isomeric endo- and exo-nitriles 
5 which were separable by flash chromatography on silica gel.  Subsequent reduction with lithium aluminum 
hydride on each nitrile isomer separately gave the corresponding aminoazaadamantanes endo-IIb and exo-IIb, 
respectively. 
 With the requisite amino(methyl)azanoradamantanes in hand, it remained to couple these amines with 
the appropriate benzoic acid derivative as shown in Scheme IV.  4-Acetamido-5-chloro-2-methoxybenzoic acid 
6 was treated with 1,1'-carbonyldiimidazole (CDI) followed by the appropriate amino(alkyl)azanoradamantane 
(Z-NH2) followed by deprotection with methanolic potassium hydroxide (except for 8f-h, which were tested as 
the acetamides).  More conveniently,  4-amino-5-chloro-2-methoxybenzoic acid 7 can be treated directly with 
CDI followed by the appropriate amine to give the benzamide 8 (R=H). 
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 The 5-HT4 agonist activities are summarized in Table I, and SC-52491 (8a) is included as a reference 
standard.  The endo derivative 8b showed modest 5-HT4 agonist activity in the rat tunica muscularis mucosae 
assay13 with an EC50 of 712 nM, but the exo isomer 8b was twice as potent with an EC50 of 382 nM.  We 
observed that epimeric homologation increases the potency in the azaadamantane series.12  However, the 5-
HT4 agonist potency was comparable for 8d and 8c. 
 The corresponding acetamide derivatives 8f, 8g, and 8h (1:1 epimeric mixture) were essentially devoid 
of 5-HT4 activity.  The acetamide 8f did exhibit rather weak 5-HT4 agonism (3.3 uM) and the unparallel slope 
observed for this compound suggested that this analog may have been acting as a partial agonist.  It is not 
known if these compounds have 5-HT4 antagonist activity. 
 The derivative 8i was the most potent meso-azanoradamantane examined in this study, exhibiting an 
EC50 of 217 nM.  The homolog 8j was almost an order of magnitude less potent. 
 Azanoradamantane benzamide 8i was selected for further study on the basis of its more potent 5-HT4 
agonist activity.  The compound is also a potent 5-HT3 antagonist, having a Ki of 5.0 (0.5) nM in the 5-HT3 
binding assay of Kilpatrick,14 and exhibiting  70% inhibition of the serotonin 5-HT3-mediated bradycardia in 
the Bezold-Jarisch reflex model15 in mice at 1 mpk after I.P. administration.  The compound was selective 
with respect to binding at the dopamine D2 receptor (IC50 >10,000 nM). 
 In summary, we have synthesized two new series of amino(alkyl)azanoradamantane benzamides which 
exhibit 5-HT4 agonism as well as affinity for the 5-HT3 receptor.  SC-55387 was the most potent 5-HT4 
agonist in the present study with an IC50 of 217 nM in the rat TMM assay and a Ki of 5.0 (0.5) nM at the 5-
HT3 receptor.  These meso-compounds have the distinct advantage of being achiral, although the compounds 
of the present series were not as potent as SC-52491 in 5-HT4 agonist activity or 5-HT3 antagonist activity. 
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